Clinical & Diagnostic
Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has offic...
August 27, 2025 | Regulatory
Development of gene-editing technology for Pasteurella bacteriophages using the IMPA™ platform Establishment of an advanced platform tec...
August 27, 2025 | News
Akeso Inc. announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibod...
August 26, 2025 | News
Eligible patients can receive TTFields therapy through the Spanish National Health System Novocure announced that Spain’s Ministry of Heal...
August 26, 2025 | News
BioPharma APAC spoke with Jane Li, Senior Director, Pharma CDx and CRO Partnership at Thermo Fisher Scientific, about the development of the Oncomine&trade...
August 25, 2025 | Expert Insight
SMSbiotech, a San Diego–based leader in regenerative medicine, announced the initiation of its first-in-human Phase 1 clinical trial for C...
August 22, 2025 | News
BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Con...
August 22, 2025 | News
RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...
August 20, 2025 | News
Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety ...
August 20, 2025 | Regulatory
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...
August 20, 2025 | News
Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with modera...
August 18, 2025 | News
Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as...
August 15, 2025 | News
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and...
August 14, 2025 | News
Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endp...
August 14, 2025 | News
Most Read
Bio Jobs
News
Editor Picks